# Cognitive, mood and speech effects on lorlatinib, and cognitive effects on avapritinib

Source: https://onco.cc/protocols/cognitive-and-mood-effects-on-lorlatinib-and-avapritinib/  
OnCo record `cognitive-and-mood-effects-on-lorlatinib-and-avapritinib` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lorlatinib and avapritinib can affect memory, thinking and mood; lorlatinib can also change speech or cause hallucinations. These effects usually improve when the dose is paused or lowered, so tell your team about new forgetfulness, confusion, mood changes, thoughts of suicide, or seeing or hearing things that are not real. The EU lorlatinib leaflet says immediately. Family may notice first.

## Summary

Lorlatinib: in the US label, central nervous system effects occurred in 52% of 476 patients (cognitive 28%, mood 21%, sleep 12%, speech 11%, psychotic 7%, seizures 1.9%), with a median time to first onset of 1.4 months; 2.1% stopped permanently for one, 10% paused and 8% had a dose reduction. The EU SmPC gives cognitive effects in 27.4%, mood 21.4%, speech 8.2% and psychotic effects 6.9%, and calls them generally mild, transient and reversible on dose delay or reduction. The reader's own team's protocol comes first.

Lorlatinib dose rules. US label: grade 1, continue at the same dose or withhold until recovery to baseline, then the same or a reduced dose; grade 2 or 3, withhold until grade 0 or 1 and resume at a reduced dose; grade 4, permanently discontinue. The EU SmPC has the same grade 2 or 3 and grade 4 rules and no grade 1 row; its definition does not include seizures or sleep. Dose levels are 75 mg and then 50 mg once daily.

Avapritinib: cognitive adverse reactions occurred in 33% of 995 patients in the US label (41% of 601 with GIST). The US and EU grade rules match, though the US table prints them under GIST or advanced systemic mastocytosis and the EU table under all three indications: grade 1, continue at the same or a reduced dose, or pause until baseline or resolution; grade 2 or 3, pause until baseline, grade 1 or resolution, then the same or a reduced dose; grade 4, permanently discontinue. The EU SmPC adds that people with GIST or advanced systemic mastocytosis are monitored clinically and must notify their healthcare professional immediately. A change in mental state on avapritinib can also be a sign of bleeding in the brain, for which both labels stop the medicine for good.

Beyond the labels, the advice for lorlatinib (preparing the person and family, looking for other causes, how early to interrupt, when to refer) comes from expert papers funded or supported by Pfizer, the maker of lorlatinib, or (the 2019 paper) written with Pfizer employees and Pfizer-funded medical writing. They differ on how early to interrupt: the Italian panel says as soon as effects emerge; the 2019 paper says to consider interrupting at grade 1; a Latin American panel says to continue at the current dose at grade 1; in the CROWN trial 58% of events needed, per protocol, no medical intervention.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: CNS effects of lorlatinib; lorlatinib brain fog; memory problems on lorlatinib; mood changes on lorlatinib; hallucinations on lorlatinib; cognitive effects of avapritinib; memory impairment on avapritinib; neurocognitive adverse events of ALK inhibitors

## Connected records

- protocols: [Distress screening with the distress thermometer, and referral by need](https://onco.cc/protocols/distress-screening-and-referral/), [Driving, flying and travel during cancer treatment](https://onco.cc/protocols/driving-flying-and-travel-during-cancer-treatment/), [Drug, herbal and food interaction review for anticancer treatment](https://onco.cc/protocols/anticancer-drug-interaction-review/), [Fluid retention, swelling and pleural effusion on kinase inhibitors and MET-targeted drugs](https://onco.cc/protocols/fluid-retention-and-effusions-on-kinase-inhibitors/), [Raised cholesterol and triglycerides, and weight gain, on lorlatinib, bexarotene and elacestrant](https://onco.cc/protocols/raised-lipids-and-weight-gain-on-lorlatinib-bexarotene-and-elacestrant/)
- drugs: [Avapritinib](https://onco.cc/drugs/avapritinib/), [Lorlatinib](https://onco.cc/drugs/lorlatinib/)
- terms: [CTCAE toxicity grading (grade 3-4 adverse events)](https://onco.cc/terms/ctcae-grading/), [Dose reduction, interruption and discontinuation](https://onco.cc/terms/dose-modification/)

---
JSON: https://onco.cc/api/v1/entities/cognitive-and-mood-effects-on-lorlatinib-and-avapritinib.json